Brokerages Set Savara Inc. (NASDAQ:SVRA) Price Target at $5.60

Savara Inc. (NASDAQ:SVRA) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $6.1667.

A number of equities analysts have weighed in on the stock. Guggenheim reiterated a “buy” rating and issued a $8.00 price target (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Oppenheimer upped their price target on shares of Savara from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, August 15th. HC Wainwright upgraded shares of Savara from a “neutral” rating to a “buy” rating and upped their price target for the stock from $2.00 to $5.00 in a research report on Friday, August 15th. Evercore ISI dropped their price target on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Finally, Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 28th.

Insider Buying and Selling at Savara

In other news, Director Richard J. Hawkins purchased 48,225 shares of the company’s stock in a transaction on Friday, June 20th. The stock was acquired at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the transaction, the director directly owned 115,466 shares in the company, valued at $235,550.64. This trade represents a 71.72% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently modified their holdings of SVRA. VR Adviser LLC boosted its position in shares of Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after acquiring an additional 5,626,624 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in shares of Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after acquiring an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Savara by 32.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after acquiring an additional 2,801,922 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Savara by 33.2% during the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after acquiring an additional 2,685,000 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in shares of Savara by 45.2% during the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock worth $23,103,000 after acquiring an additional 2,344,308 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

SVRA opened at $3.09 on Thursday. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. The company has a market cap of $534.08 million, a price-to-earnings ratio of -6.18 and a beta of 0.40. The company’s 50 day moving average is $2.44 and its 200 day moving average is $2.67. Savara has a 12-month low of $1.89 and a 12-month high of $4.70.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). On average, equities research analysts predict that Savara will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.